fluorouracil has been researched along with Hand Dermatosis in 72 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "For the purpose of developing a longitudinal model to predict hand-and-foot syndrome (HFS) dynamics in patients receiving capecitabine, data from two large phase III studies were used." | 9.14 | A dynamic model of hand-and-foot syndrome in patients receiving capecitabine. ( Cassidy, J; Dartois, C; Freyer, G; Girard, P; Hénin, E; Hoff, PM; Sirzen, F; Tod, M; Twelves, C; VanCutsem, E; You, B; Zuideveld, KP, 2009) |
| "Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatment has been definitively demonstrated." | 9.14 | Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. ( Berenberg, JL; Christian, D; Delaune, R; Loprinzi, CL; Menon, SP; Pajon, ER; Qin, R; Rowland, KM; Satele, DV; Thomas, S; Wolf, SL, 2010) |
| "Capecitabine is an established therapy for metastatic breast cancer." | 9.14 | Study of low-dose capecitabine monotherapy for metastatic breast cancer. ( Abe, C; Akagi, K; Masuda, N; Nakayama, T; Nishida, Y; Noguchi, S; Ogino, N; Sakamoto, J; Taguchi, T; Yoshidome, K; Yoshikawa, Y, 2010) |
| "To determine whether concurrent pyridoxine therapy can prevent the development of hand-foot syndrome (HFS) in patients being treated with capecitabine." | 9.14 | Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. ( Chang, HM; Chun, YJ; Kang, YK; Kim, MS; Kim, TW; Lee, JL; Lee, SS; Lee, SY; Ryu, MH; Yoon, DH, 2010) |
| "This study was conducted to determine, in patients with advanced-stage breast cancer, the maximum tolerated dose (MTD) of capecitabine administered orally for 7 days followed by a 7-day rest (7/7), a schedule based on a mathematical method for the optimization of anticancer drug scheduling." | 9.13 | Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. ( Dugan, U; Edwards, C; Feigin, K; Hudis, C; Norton, L; Patil, S; Tan, KL; Theodoulou, M; Traina, TA, 2008) |
| "This phase II study evaluated a modified Japanese capecitabine regimen as first-line treatment for advanced/metastatic colorectal cancer." | 9.11 | A phase II Japanese study of a modified capecitabine regimen for advanced or metastatic colorectal cancer. ( Kondo, Y; Nishisho, I; Sakamoto, J; Sakamoto, N; Takemiya, S, 2004) |
| "Out of various high-dose 5-fluorouracil (5-FU) regimens given with or without folinic acid (FA), the optimal 5-FU schedule has still to be defined as treatment for metastatic colorectal cancer (CRC)." | 9.10 | Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil. A prospective cohort study. ( Boehme, M; Galle, PR; Gutzler, F; Moehler, M; Raeth, U; Rudi, J; Steinmann, S; Stremmel, W, 2003) |
| "A double-blind study was carried out to compare the action of 5-fluorouracil and 10% salicylic acid varnish with that of a 10% salicylic acid varnish on common warts." | 9.04 | 5-Fluorouracil in the treatment of common warts of the hands. A double-blind study. ( Goncalves, JC, 1975) |
| "Hand-foot syndrome (HFS) is one of the most relevant dose-limiting adverse effects of capecitabine, an oral prodrug of 5-fluorouracil used in the standard treatment of breast and colorectal cancer." | 7.77 | A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. ( Alonso, MR; Benítez, J; Caronia, D; de la Torre, J; Díaz-Rubio, E; García-Sáenz, JA; González-Neira, A; Martin, M; Moreno, LT; Pita, G; Sastre, J, 2011) |
| "Prophylactic pyridoxine was given to 38 patients receiving capecitabine (alone or in combination with cyclophosphamide) for metastatic breast cancer and compared with historical data from 40 patients receiving capecitabine without pyridoxine in our clinic." | 7.76 | Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer. ( Fujita, T; Hayashi, H; Iwata, H; Kimura, M; Kondo, N; Toyama, T; Tsunoda, N; Tsuzuki, N; Yamashita, H; Yamashita, T; Yoshimoto, N, 2010) |
| "Hand-foot syndrome is a common adverse effect of therapy with capecitabine (Xeloda) for the treatment of various carcinomas." | 7.76 | Increased mast cell density in capecitabine-induced hand-foot syndrome: a new pathologic finding. ( Fraga, G; Gadzia, J; Latif, S, 2010) |
| "A hospital based cross-sectional retrospective study was conducted to determine the frequency of hand foot syndrome (HFS) with Capecitabine as a single agent and in combination with Oxaliplatin." | 7.76 | High frequency of hand foot syndrome with capecitabine. ( Azman, N; Haron, M; Kamil, M; Khalid, I; Yosuff, N, 2010) |
| " The objective of our study was to describe the incidence and response to treatment of the hand-foot syndrome (HFS) and the compliance with treatment of patients with stage IIB, IIIA, IIIB, and IIIC colon cancer that were treated with capecitabine alone as adjuvant therapy." | 7.75 | Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy. ( Chun, HK; Lee, WS; Lee, WY; Son, HS; Yun, SH, 2009) |
| "Hyperpigmentation of the hands and feet is a rare side effect with capecitabine chemotherapy and appeared to predict impending grade 2 HFS in our patients." | 7.74 | Palmar-plantar hyperpigmentation with capecitabine in adjuvant colon cancer. ( Easaw, JC; Vickers, MM, 2008) |
| "A 72-year-old patient with esophageal carcinoma developed a severe hand-foot syndrome during second-line therapy with the oral fluoropyrimidine capecitabine." | 7.74 | [Hand-foot syndrome with capecitabine therapy]. ( Hengge, UR; Marini, A, 2007) |
| "The aim of this study was to examine in detail the incidence and severity of hand-foot syndrome in advanced colorectal cancer patients receiving 5-fluorouracil (5-FU) and leucovorin (L-LV) chemotherapy." | 7.69 | Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. ( Barzacchi, C; Chiara, S; Di Somma, C; Meszaros, P; Nobile, MT; Rosso, R; Sanguineti, O; Vincenti, M, 1997) |
| "The limiting toxicity of low dose continuous infusion 5-fluorouracil (200-300 mg/m2/day) is often palmar-plantar erythrodysesthesia (PPE)." | 7.68 | Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. ( Dahlberg, S; Fabian, CJ; Giri, S; Molina, R; Slavik, M; Stephens, R, 1990) |
| "Capecitabine is a chemotherapeutic drug for use in cancers." | 5.35 | Topical henna for capecitabine induced hand-foot syndrome. ( Guzin, G; Yucel, I, 2008) |
| "Capecitabine was developed as a prodrug of 5-fluorouracil (FU), with the goal of improving tolerability and intratumour drug concentrations through tumour-specific conversion to the active drug against numerous types of neoplasms." | 5.34 | Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome? ( Do, JE; Kim, YC, 2007) |
| " The dosage should be reduced or therapeutic regimen changed." | 5.34 | [Unilateral acral necrosis as a minor form of hand-foot syndrome. Patient with unilateral acral necrosis secondary to capecitabine therapy for metastatic breast cancer]. ( Ockenfels, HM; Saborowski, A; Sauter, C, 2007) |
| "Capecitabine is an antineoplastic agent used for the treatment of patients with metastatic solid tumors (breast and colon)." | 5.34 | [Capecitabine-induced hyperpigmentation]. ( Galán-Gutiérrez, M; Jiménez-Puya, R; Moreno-Giménez, JC; Rodríguez-Bujaldón, AL; Vázquez-Bayo, C, 2007) |
| "This patient with DPD deficiency manifested a variant of HFS." | 5.33 | Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. ( Diasio, R; Elfiky, A; Saif, MW, 2006) |
| "For the purpose of developing a longitudinal model to predict hand-and-foot syndrome (HFS) dynamics in patients receiving capecitabine, data from two large phase III studies were used." | 5.14 | A dynamic model of hand-and-foot syndrome in patients receiving capecitabine. ( Cassidy, J; Dartois, C; Freyer, G; Girard, P; Hénin, E; Hoff, PM; Sirzen, F; Tod, M; Twelves, C; VanCutsem, E; You, B; Zuideveld, KP, 2009) |
| "Patients with histologically confirmed breast cancer or colorectal cancer receiving single agent capecitabine started at 2000 to 2500 mg/m(2) daily from day 1 to 14 every 3 weeks were randomly assigned to receive 200 mg or 400 mg daily of pyridoxine for PPE prophylaxis." | 5.14 | Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia. ( Chalermchai, T; Sriuranpong, V; Suwanrusme, H; Tantiphlachiva, K; Voravud, N, 2010) |
| "Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatment has been definitively demonstrated." | 5.14 | Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. ( Berenberg, JL; Christian, D; Delaune, R; Loprinzi, CL; Menon, SP; Pajon, ER; Qin, R; Rowland, KM; Satele, DV; Thomas, S; Wolf, SL, 2010) |
| "To compare the efficacy and toxicity of capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin (5-Fu/LV) plus oxaliplatin (FOLFOX4) regimens as adjuvant chemotherapy for stage III colorectal cancer." | 5.14 | [Efficacy and toxicity analysis of XELOX and FOLFOX4 regimens as adjuvant chemotherapy for stage III colorectal cancer]. ( Fang, F; Li, DC; Lu, GC, 2010) |
| "Capecitabine is an established therapy for metastatic breast cancer." | 5.14 | Study of low-dose capecitabine monotherapy for metastatic breast cancer. ( Abe, C; Akagi, K; Masuda, N; Nakayama, T; Nishida, Y; Noguchi, S; Ogino, N; Sakamoto, J; Taguchi, T; Yoshidome, K; Yoshikawa, Y, 2010) |
| "To determine whether concurrent pyridoxine therapy can prevent the development of hand-foot syndrome (HFS) in patients being treated with capecitabine." | 5.14 | Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. ( Chang, HM; Chun, YJ; Kang, YK; Kim, MS; Kim, TW; Lee, JL; Lee, SS; Lee, SY; Ryu, MH; Yoon, DH, 2010) |
| "This study was conducted to determine, in patients with advanced-stage breast cancer, the maximum tolerated dose (MTD) of capecitabine administered orally for 7 days followed by a 7-day rest (7/7), a schedule based on a mathematical method for the optimization of anticancer drug scheduling." | 5.13 | Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. ( Dugan, U; Edwards, C; Feigin, K; Hudis, C; Norton, L; Patil, S; Tan, KL; Theodoulou, M; Traina, TA, 2008) |
| "This phase II study evaluated a modified Japanese capecitabine regimen as first-line treatment for advanced/metastatic colorectal cancer." | 5.11 | A phase II Japanese study of a modified capecitabine regimen for advanced or metastatic colorectal cancer. ( Kondo, Y; Nishisho, I; Sakamoto, J; Sakamoto, N; Takemiya, S, 2004) |
| "Out of various high-dose 5-fluorouracil (5-FU) regimens given with or without folinic acid (FA), the optimal 5-FU schedule has still to be defined as treatment for metastatic colorectal cancer (CRC)." | 5.10 | Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil. A prospective cohort study. ( Boehme, M; Galle, PR; Gutzler, F; Moehler, M; Raeth, U; Rudi, J; Steinmann, S; Stremmel, W, 2003) |
| "A double-blind study was carried out to compare the action of 5-fluorouracil and 10% salicylic acid varnish with that of a 10% salicylic acid varnish on common warts." | 5.04 | 5-Fluorouracil in the treatment of common warts of the hands. A double-blind study. ( Goncalves, JC, 1975) |
| "Hand-foot syndrome is a highly unpleasant adverse reaction caused by treatment protocols containing capecitabine (an orally administered drug), docetaxel, liposomal doxorubicin infusions or continuously infused 5-fluorouracil." | 4.87 | [Main treatment and preventive measures for hand-foot syndrome, a dermatologic side effect of cancer therapy]. ( Bartal, A; Liszkay, G; Mátrai, Z; Szûcs, A, 2011) |
| "A 60-year-old Ghanese woman was treated with radiotherapy and capecitabine for metastatic breast cancer." | 3.77 | [A woman with palmar and plantar hyperpigmentation]. ( van Tienhoven, G; Wilmink, JW, 2011) |
| "Hand-foot syndrome (HFS) is one of the most relevant dose-limiting adverse effects of capecitabine, an oral prodrug of 5-fluorouracil used in the standard treatment of breast and colorectal cancer." | 3.77 | A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. ( Alonso, MR; Benítez, J; Caronia, D; de la Torre, J; Díaz-Rubio, E; García-Sáenz, JA; González-Neira, A; Martin, M; Moreno, LT; Pita, G; Sastre, J, 2011) |
| "A hospital based cross-sectional retrospective study was conducted to determine the frequency of hand foot syndrome (HFS) with Capecitabine as a single agent and in combination with Oxaliplatin." | 3.76 | High frequency of hand foot syndrome with capecitabine. ( Azman, N; Haron, M; Kamil, M; Khalid, I; Yosuff, N, 2010) |
| "Hand-foot syndrome is a common adverse effect of therapy with capecitabine (Xeloda) for the treatment of various carcinomas." | 3.76 | Increased mast cell density in capecitabine-induced hand-foot syndrome: a new pathologic finding. ( Fraga, G; Gadzia, J; Latif, S, 2010) |
| "Prophylactic pyridoxine was given to 38 patients receiving capecitabine (alone or in combination with cyclophosphamide) for metastatic breast cancer and compared with historical data from 40 patients receiving capecitabine without pyridoxine in our clinic." | 3.76 | Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer. ( Fujita, T; Hayashi, H; Iwata, H; Kimura, M; Kondo, N; Toyama, T; Tsunoda, N; Tsuzuki, N; Yamashita, H; Yamashita, T; Yoshimoto, N, 2010) |
| " The objective of our study was to describe the incidence and response to treatment of the hand-foot syndrome (HFS) and the compliance with treatment of patients with stage IIB, IIIA, IIIB, and IIIC colon cancer that were treated with capecitabine alone as adjuvant therapy." | 3.75 | Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy. ( Chun, HK; Lee, WS; Lee, WY; Son, HS; Yun, SH, 2009) |
| "Hyperpigmentation of the hands and feet is a rare side effect with capecitabine chemotherapy and appeared to predict impending grade 2 HFS in our patients." | 3.74 | Palmar-plantar hyperpigmentation with capecitabine in adjuvant colon cancer. ( Easaw, JC; Vickers, MM, 2008) |
| "A 72-year-old patient with esophageal carcinoma developed a severe hand-foot syndrome during second-line therapy with the oral fluoropyrimidine capecitabine." | 3.74 | [Hand-foot syndrome with capecitabine therapy]. ( Hengge, UR; Marini, A, 2007) |
| " This article presents the case of a 69-year-old African American man with a gastric adenocarcinoma status post gastrectomy who received 5-fluorouracil (5-FU) plus leucovorin for 5 days, to be followed by radiation plus capecitabine given 5 days per week for 5 weeks, and then 8 weeks of capecitabine monotherapy." | 3.74 | Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity? ( Saif, MW; Sandoval, A, 2008) |
| "The aim of this study was to examine in detail the incidence and severity of hand-foot syndrome in advanced colorectal cancer patients receiving 5-fluorouracil (5-FU) and leucovorin (L-LV) chemotherapy." | 3.69 | Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. ( Barzacchi, C; Chiara, S; Di Somma, C; Meszaros, P; Nobile, MT; Rosso, R; Sanguineti, O; Vincenti, M, 1997) |
| "The limiting toxicity of low dose continuous infusion 5-fluorouracil (200-300 mg/m2/day) is often palmar-plantar erythrodysesthesia (PPE)." | 3.68 | Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. ( Dahlberg, S; Fabian, CJ; Giri, S; Molina, R; Slavik, M; Stephens, R, 1990) |
| "Capecitabine combined with fractionated cisplatin is highly effective and well tolerated as a first-line treatment for advanced gastric cancer, with comparable results to 5-Fu plus cisplatin combination therapy." | 2.73 | [Capecitabine combined with cisplatin as first-line therapy in Chinese patients with advanced gastric carcinoma-a phase II clinical study]. ( Bai, YX; Chen, L; Chen, S; Cheng, Y; Hu, B; Jia, TZ; Jin, ML; Li, J; Liang, J; Shen, L; Shu, YQ; Wan, DS; Wang, BC; Wen, ZZ; Yin, HR; Yu, JR; Zhang, HG; Zhou, Y, 2008) |
| "Metastatic renal cell carcinoma (RCC) has modest response rates to chemotherapy with gemcitabine and 5-fluorouracil (5-FU)." | 2.71 | A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma. ( Rini, BI; Small, EJ; Weinberg, V, 2005) |
| "Palmar-plantar erythrodysesthesia (PPE) or hand-foot syndrome (HFS) is a relatively common side effect of cytotoxic chemotherapy." | 2.44 | Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. ( Harrold, K; How, C; Webster-Gandy, JD, 2007) |
| " HFS is a leading cause of treatment interruption, dosage reduction, or, even, therapy discontinuation for patients on a capecitabine regimen." | 2.44 | Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? ( Goldberg, RM; McLeod, HL; Yen-Revollo, JL, 2008) |
| "Capecitabine is a prodrug of fluorouracil." | 1.35 | Focal acral hyperpigmentation in a patient undergoing chemotherapy with capecitabine. ( Alonso, V; Calduch, L; Jordá, E; Martín, JM; Pinazo, MI; Villalón, G, 2009) |
| "Capecitabine was designed to generate 5FU via the thymidine phosphorylase (TP) enzyme, preferentially expressed in tumoral tissues." | 1.35 | Candidate mechanisms for capecitabine-related hand-foot syndrome. ( Etienne-Grimaldi, MC; Formento, JL; Francoual, M; Hofman, P; Lacour, JP; Lassalle, S; Mari, M; Milano, G, 2008) |
| "Capecitabine has single agent activity in NPC and severe hand-foot syndrome predicts favorable outcome." | 1.35 | Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer. ( Au, GK; Chua, D; Sham, JS; Wei, WI, 2008) |
| "Capecitabine is a chemotherapeutic drug for use in cancers." | 1.35 | Topical henna for capecitabine induced hand-foot syndrome. ( Guzin, G; Yucel, I, 2008) |
| " Hand-foot syndrome (HFS) is a relatively common side effect of cytotoxic chemotherapy." | 1.35 | Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma? ( Rajebi, MR; Saif, MW; Shahrokni, A, 2009) |
| " The dosage should be reduced or therapeutic regimen changed." | 1.34 | [Unilateral acral necrosis as a minor form of hand-foot syndrome. Patient with unilateral acral necrosis secondary to capecitabine therapy for metastatic breast cancer]. ( Ockenfels, HM; Saborowski, A; Sauter, C, 2007) |
| "Capecitabine was developed as a prodrug of 5-fluorouracil (FU), with the goal of improving tolerability and intratumour drug concentrations through tumour-specific conversion to the active drug against numerous types of neoplasms." | 1.34 | Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome? ( Do, JE; Kim, YC, 2007) |
| " HFS manifests as acral erythema, with swelling and dysesthesia of the palms and plantar aspects of the feet, which in the absence of dosage reduction or drug cessation, progresses to moist desquamation and ulceration, resulting in serious infections and loss of function." | 1.34 | Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: a case report. ( Hwang, SJ; Kim, BS; Kim, HJ; Kim, YJ; Lee, SD; Nam, SH, 2007) |
| "Capecitabine is an antineoplastic agent used for the treatment of patients with metastatic solid tumors (breast and colon)." | 1.34 | [Capecitabine-induced hyperpigmentation]. ( Galán-Gutiérrez, M; Jiménez-Puya, R; Moreno-Giménez, JC; Rodríguez-Bujaldón, AL; Vázquez-Bayo, C, 2007) |
| "This patient with DPD deficiency manifested a variant of HFS." | 1.33 | Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. ( Diasio, R; Elfiky, A; Saif, MW, 2006) |
| "5-fluorouracil (5-FU) treatment is also widely utilized." | 1.31 | Cryopeeling (extensive cryosurgery) for treatment of actinic keratoses: an update and comparison. ( Chiarello, SE, 2000) |
| "5-Fluorouracil (5-FU) is an antimetabolite frequently used in the treatment of cancer." | 1.29 | Dermatological toxicity from chemotherapy containing 5-fluorouracil. ( Campanella, GA; Carrieri, G; Colucci, G; Leo, S; Tatulli, C; Taveri, R, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (19.44) | 18.7374 |
| 1990's | 6 (8.33) | 18.2507 |
| 2000's | 37 (51.39) | 29.6817 |
| 2010's | 15 (20.83) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lacouture, ME | 1 |
| Reilly, LM | 1 |
| Gerami, P | 1 |
| Guitart, J | 1 |
| Piqué-Duran, E | 1 |
| Pérez-Díaz, MJ | 1 |
| Pérez-Cejudo, JA | 1 |
| Sanz-Sánchez, T | 1 |
| Córdoba, S | 1 |
| Jiménez-Ayala, B | 1 |
| Borbujo, JM | 1 |
| Saif, MW | 4 |
| Sandoval, A | 1 |
| Hénin, E | 1 |
| You, B | 1 |
| VanCutsem, E | 1 |
| Hoff, PM | 1 |
| Cassidy, J | 1 |
| Twelves, C | 1 |
| Zuideveld, KP | 1 |
| Sirzen, F | 1 |
| Dartois, C | 1 |
| Freyer, G | 1 |
| Tod, M | 1 |
| Girard, P | 1 |
| Hu, B | 1 |
| Yu, JR | 1 |
| Wen, ZZ | 1 |
| Shu, YQ | 1 |
| Wang, BC | 1 |
| Yin, HR | 1 |
| Chen, L | 2 |
| Bai, YX | 1 |
| Liang, J | 1 |
| Cheng, Y | 1 |
| Shen, L | 1 |
| Zhou, Y | 1 |
| Zhang, HG | 1 |
| Li, J | 1 |
| Wan, DS | 2 |
| Chen, S | 1 |
| Jia, TZ | 1 |
| Jin, ML | 1 |
| Vickers, MM | 1 |
| Easaw, JC | 1 |
| Villalón, G | 1 |
| Martín, JM | 1 |
| Pinazo, MI | 1 |
| Calduch, L | 1 |
| Alonso, V | 1 |
| Jordá, E | 2 |
| Yoshimoto, N | 1 |
| Yamashita, T | 1 |
| Fujita, T | 1 |
| Hayashi, H | 1 |
| Tsunoda, N | 1 |
| Kimura, M | 1 |
| Tsuzuki, N | 1 |
| Yamashita, H | 1 |
| Toyama, T | 1 |
| Kondo, N | 1 |
| Iwata, H | 1 |
| Shahrokni, A | 1 |
| Rajebi, MR | 1 |
| Son, HS | 1 |
| Lee, WY | 1 |
| Lee, WS | 1 |
| Yun, SH | 1 |
| Chun, HK | 1 |
| Latif, S | 1 |
| Fraga, G | 1 |
| Gadzia, J | 1 |
| Lu, GC | 1 |
| Fang, F | 1 |
| Li, DC | 1 |
| Taguchi, T | 1 |
| Nakayama, T | 1 |
| Masuda, N | 1 |
| Yoshidome, K | 1 |
| Akagi, K | 1 |
| Nishida, Y | 1 |
| Yoshikawa, Y | 1 |
| Ogino, N | 1 |
| Abe, C | 1 |
| Sakamoto, J | 2 |
| Noguchi, S | 1 |
| Kang, YK | 1 |
| Lee, SS | 1 |
| Yoon, DH | 1 |
| Lee, SY | 1 |
| Chun, YJ | 1 |
| Kim, MS | 1 |
| Ryu, MH | 1 |
| Chang, HM | 1 |
| Lee, JL | 1 |
| Kim, TW | 1 |
| Kamil, M | 1 |
| Haron, M | 1 |
| Yosuff, N | 1 |
| Khalid, I | 1 |
| Azman, N | 1 |
| Chalermchai, T | 1 |
| Tantiphlachiva, K | 1 |
| Suwanrusme, H | 1 |
| Voravud, N | 1 |
| Sriuranpong, V | 1 |
| Wolf, SL | 1 |
| Qin, R | 1 |
| Menon, SP | 1 |
| Rowland, KM | 1 |
| Thomas, S | 1 |
| Delaune, R | 1 |
| Christian, D | 1 |
| Pajon, ER | 1 |
| Satele, DV | 1 |
| Berenberg, JL | 1 |
| Loprinzi, CL | 1 |
| Zhang, RX | 1 |
| Wu, XJ | 1 |
| Lu, SX | 1 |
| Pan, ZZ | 1 |
| Chen, G | 1 |
| Caronia, D | 1 |
| Martin, M | 1 |
| Sastre, J | 1 |
| de la Torre, J | 1 |
| García-Sáenz, JA | 1 |
| Alonso, MR | 1 |
| Moreno, LT | 1 |
| Pita, G | 1 |
| Díaz-Rubio, E | 1 |
| Benítez, J | 1 |
| González-Neira, A | 1 |
| Bartal, A | 1 |
| Mátrai, Z | 1 |
| Szûcs, A | 1 |
| Liszkay, G | 1 |
| van Tienhoven, G | 1 |
| Wilmink, JW | 1 |
| Ciccolini, J | 2 |
| Evrard, A | 1 |
| Lacarelle, B | 1 |
| Powers, R | 1 |
| Gordon, R | 1 |
| Roberts, K | 1 |
| Kovach, R | 1 |
| Moehler, M | 1 |
| Gutzler, F | 1 |
| Steinmann, S | 1 |
| Boehme, M | 1 |
| Raeth, U | 1 |
| Stremmel, W | 1 |
| Galle, PR | 1 |
| Rudi, J | 1 |
| Risum, S | 1 |
| Langer, SW | 1 |
| Park, YH | 1 |
| Ryoo, BY | 1 |
| Lee, HJ | 1 |
| Kim, SA | 1 |
| Chung, JH | 1 |
| Takahashi, K | 1 |
| Mori, T | 1 |
| Yamaguchi, T | 1 |
| Matsumoto, H | 1 |
| Miyamoto, H | 1 |
| Arai, K | 1 |
| Iwasaki, Y | 1 |
| Katayanagi, S | 1 |
| Kondo, Y | 1 |
| Takemiya, S | 1 |
| Sakamoto, N | 1 |
| Nishisho, I | 1 |
| Sorscher, SM | 1 |
| Fischel, JL | 1 |
| Formento, P | 1 |
| Etienne-Grimaldi, MC | 2 |
| Milano, G | 2 |
| Rini, BI | 1 |
| Weinberg, V | 1 |
| Small, EJ | 1 |
| Gugerli, O | 1 |
| Leupin, N | 1 |
| Marini, A | 1 |
| Hengge, UR | 1 |
| Elfiky, A | 1 |
| Diasio, R | 1 |
| Sauter, C | 1 |
| Saborowski, A | 1 |
| Ockenfels, HM | 1 |
| Webster-Gandy, JD | 1 |
| How, C | 1 |
| Harrold, K | 1 |
| Do, JE | 1 |
| Kim, YC | 1 |
| Lee, SD | 1 |
| Kim, HJ | 1 |
| Hwang, SJ | 1 |
| Kim, YJ | 1 |
| Nam, SH | 1 |
| Kim, BS | 1 |
| Shimomatsuya, T | 1 |
| Mitsudou, Y | 1 |
| Nakamura, T | 1 |
| Yonezawa, K | 1 |
| Shiraishi, S | 1 |
| Fujino, M | 1 |
| Maruhashi, K | 1 |
| Vázquez-Bayo, C | 1 |
| Rodríguez-Bujaldón, AL | 1 |
| Jiménez-Puya, R | 1 |
| Galán-Gutiérrez, M | 1 |
| Moreno-Giménez, JC | 1 |
| Kern, E | 1 |
| Schmidinger, M | 1 |
| Locker, GJ | 1 |
| Kopp, B | 1 |
| Yucel, I | 1 |
| Guzin, G | 1 |
| Tavares-Bello, R | 1 |
| Weiss, E | 1 |
| Amini, S | 1 |
| Yen-Revollo, JL | 1 |
| Goldberg, RM | 1 |
| McLeod, HL | 1 |
| Mari, M | 1 |
| Lassalle, S | 1 |
| Formento, JL | 1 |
| Francoual, M | 1 |
| Lacour, JP | 1 |
| Hofman, P | 1 |
| Trindade, F | 1 |
| Haro, R | 1 |
| Fariña, MC | 1 |
| Requena, L | 1 |
| Traina, TA | 1 |
| Theodoulou, M | 1 |
| Feigin, K | 1 |
| Patil, S | 1 |
| Tan, KL | 1 |
| Edwards, C | 1 |
| Dugan, U | 1 |
| Norton, L | 1 |
| Hudis, C | 1 |
| Chua, D | 1 |
| Wei, WI | 1 |
| Sham, JS | 1 |
| Au, GK | 1 |
| Chiaffitelli, C | 1 |
| Suarez Halty, L | 1 |
| Reed, WP | 1 |
| Morris, DM | 1 |
| McDonald, SG | 1 |
| Peterka, ES | 1 |
| Heine, KG | 1 |
| Leo, S | 1 |
| Tatulli, C | 1 |
| Taveri, R | 1 |
| Campanella, GA | 1 |
| Carrieri, G | 1 |
| Colucci, G | 1 |
| Chiara, S | 1 |
| Nobile, MT | 1 |
| Barzacchi, C | 1 |
| Sanguineti, O | 1 |
| Vincenti, M | 1 |
| Di Somma, C | 1 |
| Meszaros, P | 1 |
| Rosso, R | 1 |
| Kurwa, HA | 1 |
| Yong-Gee, SA | 1 |
| Seed, PT | 1 |
| Markey, AC | 1 |
| Barlow, RJ | 1 |
| de Jong, EM | 1 |
| Menke, HE | 1 |
| van Praag, MC | 1 |
| van De Kerkhof, PC | 1 |
| Chiarello, SE | 1 |
| Goncalves, JC | 1 |
| Galan, A | 1 |
| Betlloch, I | 1 |
| Ramon, D | 1 |
| Revert, A | 1 |
| Torres, V | 1 |
| Fabian, CJ | 1 |
| Molina, R | 1 |
| Slavik, M | 1 |
| Dahlberg, S | 1 |
| Giri, S | 1 |
| Stephens, R | 1 |
| Vukelja, SJ | 1 |
| Lombardo, FA | 1 |
| James, WD | 1 |
| Weiss, RB | 1 |
| Curran, CF | 1 |
| Luce, JK | 1 |
| Feldman, LD | 1 |
| Ajani, JA | 1 |
| Guillaume, JC | 1 |
| Carp, E | 1 |
| Rougier, P | 1 |
| Charpentier, P | 1 |
| André, P | 1 |
| Carde, P | 1 |
| Avril, MF | 1 |
| Caballero, GA | 1 |
| Ausman, RK | 1 |
| Quebbeman, EJ | 1 |
| Atkins, JN | 1 |
| Hernández-Perez, E | 1 |
| Lopes, CF | 1 |
| Armond, S | 1 |
| Guss, SB | 1 |
| Osbourn, RA | 1 |
| Lutzner, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-Blind Phase III Study of Pyridoxine vs Placebo for the Prevention of Capecitabine-induced Hand-Foot Syndrome[NCT00446147] | Phase 3 | 389 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer(KCSG ST14-05)[NCT01917552] | Phase 3 | 870 participants (Anticipated) | Interventional | 2013-08-19 | Recruiting | ||
| A Phase II, Randomised Controlled Trial to Evaluate the Efficacy and Safety of Moisturising Creams With or Without Palm-oil-derived Vitamin E Concentrate in Addition to Urea-based Cream or Urea-based Cream Alone in Capecitabine-associated Palmar-Plantar E[NCT05939726] | 90 participants (Anticipated) | Interventional | 2023-05-16 | Recruiting | |||
| A Phase III Randomized, Placebo-controlled, Double-blind Trial to Determine the Effectiveness of a Urea/Lactic Acid-Based Topical Keratolytic Agent and Vitamin B-6 for Prevention of Capecitabine-Induced Hand and Foot Syndrome[NCT00296036] | Phase 3 | 137 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| "Evaluation of the Restorative Efficacy of the Cosmetic Product Onco-Repair vs. Placebo on Grade 2 Hand Foot Syndrome Induced by Targeted Therapies or Conventional Chemotherapy. Randomized, Multicentre, Double Blind, Controlled Study Versus Placebo."[NCT03612011] | Phase 3 | 72 participants (Actual) | Interventional | 2018-07-12 | Completed | ||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| Randomized Controlled Trial of 308 nm Excimer Laser for Treatment of Nail Psoriasis[NCT02168933] | 8 participants (Actual) | Interventional | 2014-01-31 | Completed | |||
| Multicentre Randomized Phase II Study of Neoadjuvant Trastuzumab Plus Docetaxel With and Without Bevacizumab and Trastuzumab Plus Docetaxel Plus Non-pegylated Liposome-encapsulated Doxorubicin (NPLD) With and Without Bevacizumab in HER2-positive Early Bre[NCT01367028] | Phase 2 | 100 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A total administered dose of capecitabine until the development of grade 2 or higher hand-foot syndrome during the chemotherapy. (NCT00446147)
Timeframe: Up to 2 years
| Intervention | miligram per square meter (Median) |
|---|---|
| Placebo | 70000 |
| Pyridoxine | 70000 |
Number of patients with any grade of hand-foot syndrome (NCT00446147)
Timeframe: Up to 2 years
| Intervention | participants (Number) |
|---|---|
| Placebo | 55 |
| Pyridoxine | 57 |
A patient self-reported hand-foot syndrome (HFSD), also known as palmar-plantar erythrodysesthesia, was completed daily while applying the cream. Patients rated skin severity symptoms individually in their hands and in their feet. Definitions of symptoms, which were based on Common Terminology Criteria for Adverse Events (CTCAE) v3.0, were provided to patients. The number of patients reporting moderate to severe symptoms in either hands or feet were tabulated and percentages are reported. (NCT00296036)
Timeframe: First 3 weeks of treatment
| Intervention | percentage of participants (Number) |
|---|---|
| Urea/Lactic Acid Cream | 13.6 |
| Placebo Cream | 10.2 |
Frequency and severity of adverse events reported by patients in weekly diary and evaluated through clinical assessment by NCI CTCAE v3.0. The number of patients reporting grade 3 or higher events are reported in this outcome measure. For a full list of all events, please refer to the Adverse Events section of this report. (NCT00296036)
Timeframe: Up to 4, 21-day cycles
| Intervention | participants (Number) | |
|---|---|---|
| Grade 3+ Adverse Event | Grade 4+ Adverse Event | |
| Placebo Cream | 18 | 3 |
| Urea/Lactic Acid Cream | 21 | 3 |
This is an instrument that scores nail psoriasis severity. Severity for each nail is measured on a scale of 0-13, where crumbling, pitting, onycholysis and oil spots together are each graded 0-3, and other features (leukonychia, splinter hemorrhages, hyperkeratosis, and red spots in lunula) are scored 0 (absent) or 1 (present). Higher score indicates more severe nail psoriasis with 13 being the most severe and 0 being no nail disease present. (NCT02168933)
Timeframe: at 16 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active | 6.3 |
| Sham | 6.0 |
this is a subjective patient reported scale, 0-100, where 100 is the most severe global assessment of the patient's nail psoriasis, and 0 is clear (no nail disease present). (NCT02168933)
Timeframe: at 16 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active | 58.6 |
| Sham | 55.4 |
4 reviews available for fluorouracil and Hand Dermatosis
| Article | Year |
|---|---|
Capecitabine and hand-foot syndrome.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diagnos | 2011 |
[Main treatment and preventive measures for hand-foot syndrome, a dermatologic side effect of cancer therapy].
Topics: Antineoplastic Agents; Capecitabine; Cytarabine; Deoxycytidine; Docetaxel; Doxorubicin; Fluorouracil | 2011 |
Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre.
Topics: Activities of Daily Living; Antineoplastic Agents; Cancer Care Facilities; Cryotherapy; Cytarabine; | 2007 |
Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?
Topics: Antineoplastic Agents; Dihydrouracil Dehydrogenase (NADP); Enzyme Inhibitors; Fluorouracil; Foot Der | 2008 |
16 trials available for fluorouracil and Hand Dermatosis
| Article | Year |
|---|---|
A dynamic model of hand-and-foot syndrome in patients receiving capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluoroura | 2009 |
[Capecitabine combined with cisplatin as first-line therapy in Chinese patients with advanced gastric carcinoma-a phase II clinical study].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
[Efficacy and toxicity analysis of XELOX and FOLFOX4 regimens as adjuvant chemotherapy for stage III colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2010 |
Study of low-dose capecitabine monotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant | 2010 |
Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dou | 2010 |
Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dou | 2010 |
Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dou | 2010 |
Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dou | 2010 |
Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Col | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; De | 2011 |
The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; De | 2011 |
The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; De | 2011 |
The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; De | 2011 |
Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil. A prospective cohort study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorec | 2003 |
A phase II Japanese study of a modified capecitabine regimen for advanced or metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progre | 2004 |
A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2005 |
Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; | 2008 |
A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses.
Topics: Administration, Topical; Aged; Antimetabolites; Female; Fluorouracil; Forearm; Hand Dermatoses; Huma | 1999 |
Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration-enhancing vehicle: a double-blind study.
Topics: Adult; Aged; Antimetabolites; Double-Blind Method; Female; Fluorouracil; Hand Dermatoses; Humans; Ma | 1999 |
5-Fluorouracil in the treatment of common warts of the hands. A double-blind study.
Topics: Abattoirs; Administration, Topical; Animals; Chickens; Clinical Trials as Topic; Drug Combinations; | 1975 |
[Therapeutic trial with 5-fluorouracil ointment].
Topics: Adult; Aged; Carcinoma, Basal Cell; Clinical Trials as Topic; Evaluation Studies as Topic; Facial Ne | 1970 |
52 other studies available for fluorouracil and Hand Dermatosis
| Article | Year |
|---|---|
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinom | 2008 |
Pyogenic granuloma-like lesions caused by capecitabine therapy.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Deoxycytidine; Drug Eruptions; Fingers; Fl | 2008 |
[5-Fluorouracil-induced reticular hyperpigmentation].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2008 |
Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity?
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Black or African American; Capecitabine; Deox | 2008 |
Palmar-plantar hyperpigmentation with capecitabine in adjuvant colon cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Female; Fluorouraci | 2008 |
Focal acral hyperpigmentation in a patient undergoing chemotherapy with capecitabine.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Dermoscopy; Female; | 2009 |
Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deo | 2010 |
Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F | 2009 |
Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasm | 2009 |
Increased mast cell density in capecitabine-induced hand-foot syndrome: a new pathologic finding.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Cell Count; Deoxycytidine; Female; Fluorouracil | 2010 |
High frequency of hand foot syndrome with capecitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cross-Sectional St | 2010 |
A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Base Sequence; Binding Sites; Breas | 2011 |
[A woman with palmar and plantar hyperpigmentation].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil | 2011 |
A CDD polymorphism as predictor of capecitabine-induced hand-foot syndrome--letter.
Topics: Antimetabolites, Antineoplastic; Cytidine Deaminase; Deoxycytidine; Erythema; Female; Fluorouracil; | 2012 |
Symmetrical drug-related intertriginous and flexural exanthema secondary to topical 5-fluorouracil.
Topics: Administration, Cutaneous; Drug Eruptions; Exanthema; Fluorouracil; Hand Dermatoses; Humans; Immunos | 2012 |
[Plantar-palmar erythrodysesthesia. A new and relatively frequent side effect in antineoplastic treatment].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response R | 2003 |
High incidence of severe hand-foot syndrome during capecitabine-docetaxel combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluo | 2003 |
[A new systemic combination chemotherapy to be provided at home for patients with unresectable recurrent colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Administration | 2003 |
Penile involvement with hand-foot syndrome.
Topics: Antineoplastic Agents; Drug Eruptions; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male; | 2004 |
Lack of contribution of dihydrofluorouracil and alpha-fluoro-beta-alanine to the cytotoxicity of 5'-deoxy-5-fluorouridine on human keratinocytes.
Topics: Antineoplastic Agents; beta-Alanine; Cell Line, Tumor; Dihydrouracil Dehydrogenase (NADP); Dose-Resp | 2004 |
[Blisters unlike others].
Topics: Aged; Antimetabolites, Antineoplastic; Blister; Capecitabine; Deoxycytidine; Drug Eruptions; Female; | 2006 |
[Hand-foot syndrome with capecitabine therapy].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Esophageal Neopl | 2007 |
Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deficiency Diseases; Deoxycyt | 2006 |
[Unilateral acral necrosis as a minor form of hand-foot syndrome. Patient with unilateral acral necrosis secondary to capecitabine therapy for metastatic breast cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Erythema; Fema | 2007 |
Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome?
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; F | 2007 |
Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: a case report.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorourac | 2007 |
[A case of severe hand-foot syndrome caused by capecitabine].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration | 2007 |
[Capecitabine-induced hyperpigmentation].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Female; F | 2007 |
[Management of capecitabine-induced hand-foot syndrome by local phytotherapy].
Topics: Antimetabolites, Antineoplastic; Calendula; Capecitabine; Deoxycytidine; Fluorouracil; Foot Dermatos | 2007 |
Topical henna for capecitabine induced hand-foot syndrome.
Topics: Administration, Cutaneous; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine | 2008 |
Capecitabine-induced hand-foot syndrome and cutaneous hyperpigmentation in an elderly vitiligo patient.
Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; | 2007 |
A novel treatment for knuckle pads with intralesional Fluorouracil.
Topics: Adult; Antimetabolites; Female; Finger Joint; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans | 2007 |
Candidate mechanisms for capecitabine-related hand-foot syndrome.
Topics: Adult; Antimetabolites, Antineoplastic; Biopsy; Capecitabine; Cell Proliferation; Deoxycytidine; Fem | 2008 |
Hand-foot syndrome with sclerodactyly-like changes in a patient treated with capecitabine.
Topics: Adenocarcinoma; Administration, Oral; Biopsy, Needle; Capecitabine; Deoxycytidine; Dose-Response Rel | 2008 |
Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease-Free Survival; Dr | 2008 |
[Experience on topical 5-fluoruracil- (5-FU) in cutaneous carcinomatosis. I. Test on the efficiency of topical 5-FU].
Topics: Carcinoma, Basal Cell; Cheilitis; Facial Dermatoses; Female; Fluorouracil; Hand Dermatoses; Humans; | 1966 |
Maculopapular eruption resulting from systemic administration of 5-fluorouracil.
Topics: Aged; Breast Neoplasms; Drug Eruptions; Female; Fluorouracil; Hand Dermatoses; Humans | 1984 |
Porokeratosis (Mibelli): treatment with topical 5-fluorouracil.
Topics: Administration, Topical; Adult; Fluorouracil; Hand Dermatoses; Humans; Keratosis; Male; Skin; Syndro | 1983 |
Treatment of multiple keratoacanthomas with fluorouracil.
Topics: Arm; Fluorouracil; Hand Dermatoses; Humans; Keratoacanthoma; Male; Middle Aged; Skin Diseases | 1983 |
Dermatological toxicity from chemotherapy containing 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 1994 |
Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 1997 |
Cryopeeling (extensive cryosurgery) for treatment of actinic keratoses: an update and comparison.
Topics: Carcinoma, Squamous Cell; Chemexfoliation; Cryosurgery; Facial Dermatoses; Female; Fluorouracil; Fol | 2000 |
Painful, red hands. A side effect of 5-fluorouracil by continuous perfusion.
Topics: Adenocarcinoma; Colonic Neoplasms; Drug Eruptions; Female; Fluorouracil; Hand Dermatoses; Humans; Mi | 1991 |
Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion.
Topics: Colonic Neoplasms; Edema; Erythema; Fluorouracil; Follow-Up Studies; Foot Dermatoses; Hand Dermatose | 1990 |
Pyridoxine for the palmar-plantar erythrodysesthesia syndrome.
Topics: Dermatitis, Exfoliative; Fluorouracil; Hand Dermatoses; Humans; Male; Middle Aged; Nervous System Di | 1989 |
Fluorouracil and palmar-plantar erythrodysesthesia.
Topics: Erythema; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Pain | 1989 |
Fluorouracil-associated dermatitis of the hands and feet.
Topics: Adult; Drug Eruptions; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male | 1985 |
[Cutaneomucous adverse effects of continuous infusion of 5-fluorouracil: 12 cases].
Topics: Adult; Drug Eruptions; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Infusions, In | 1988 |
Long-term, ambulatory, continuous IV infusion of 5-FU for the treatment of advanced adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Breast Neoplasms; Drug Eruptions; Female; Fluorouracil | 1985 |
Fluorouracil and the palmar-plantar erythrodysesthesia syndrome.
Topics: Dermatitis, Exfoliative; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Middle Aged | 1985 |
Letter: A simple treatment for plantar warts.
Topics: Electrosurgery; Fluorouracil; Hand Dermatoses; Humans; Trichloroacetic Acid; Warts | 1974 |
Porokeratosis plantaris, palmaris, et disseminata. A third type of porokeratosis.
Topics: Adolescent; Adult; Age Factors; Aged; Biopsy; Carcinoma, Squamous Cell; Child; Female; Fluorouracil; | 1971 |